Description

Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin[1][2][3].—Cancer-programmed cell death–C45H68N6O9—-[1]Bai R, et al. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol. 1992 Jun 23;43(12):2637-45.|[2]Sato M, et al. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int J Oncol. 2007 Jun;30(6):1453-9.|[3]Gianolio DA, et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol. 2012 Sep;70(3):439-49.|[4]Ali MA, et al. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines. Anticancer Res. 1998 Mar-Apr;18(2A):1021-6.–123884-00-4–837.06—-O=C(N(C1=O)[C@H](C(OC)=C1)CC2=CC=CC=C2)[C@H](C(C)C)OC([C@H](CCC3)N3C([C@H](CCC4)N4C([C@H](C(C)C)N(C)C([C@H](C(C)C)NC([C@@H](N(C)C)C(C)C)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–ADC Cytotoxin;Apoptosis;Microtubule/Tubulin–Auristatin–Antibody-drug Conjugate/ADC Related;Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton–Peptides